POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS - Generic Drug Details

What are the generic drug sources for polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous and what is the scope of freedom to operate?

Polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous is the generic ingredient in twelve branded drugs marketed by Quagen, Azurity, Extrovis, Novel Labs Inc, Paddock Llc, Strides Pharma, Vintage Pharms, Dynapharm, E Z Em, Goldline, and Sandoz, and is included in thirteen NDAs. Additional information is available in the individual branded drug profile pages.

Six suppliers are listed for this compound.

Summary for POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

US Patents:	0
Tradenames:	12
Applicants:	11
NDAs:	13
Finished Product Suppliers / Packagers:	6
Clinical Trials:	1
DailyMed Link:	POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS at DailyMed

Recent Clinical Trials for POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Temple University	Phase 4

See all POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS clinical trials

Pharmacology for POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

Drug Class	Osmotic Laxative Potassium Salt
Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Stimulation Large Intestine Fluid/Electrolyte Secretion

Anatomical Therapeutic Chemical (ATC) Classes for POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

A06AD	Osmotically acting laxatives
A06A	DRUGS FOR CONSTIPATION
A06	DRUGS FOR CONSTIPATION
A	Alimentary tract and metabolism

A12BA	Potassium
A12B	POTASSIUM
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CA	Sodium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

A12CA	Sodium
A12C	OTHER MINERAL SUPPLEMENTS
A12	MINERAL SUPPLEMENTS
A	Alimentary tract and metabolism

B05CB	Salt solutions
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05CB	Salt solutions
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

B05XA	Electrolyte solutions
B05X	I.V. SOLUTION ADDITIVES
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

US Patents and Regulatory Information for POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sandoz	PEG-LYTE	polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous	FOR SUSPENSION;ORAL	073098-001	Aug 31, 1993		DISCN	No	No
Dynapharm	COLOVAGE	polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous	FOR SUSPENSION;ORAL	071320-001	Apr 20, 1988		DISCN	No	No
Quagen	COLYTE-FLAVORED	polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous	FOR SOLUTION;ORAL	018983-009	Nov 14, 1991		DISCN	No	No
Quagen	COLYTE	polyethylene glycol 3350; potassium chloride; sodium bicarbonate; sodium chloride; sodium sulfate anhydrous	FOR SOLUTION;ORAL	018983-005	Oct 26, 1984		DISCN	No	No

Market Dynamics and Financial Trajectory for Key Pharmaceutical Ingredients

Last updated: February 16, 2026

The pharmaceutical ingredients polyethylene glycol 3350, potassium chloride, sodium bicarbonate, sodium chloride, and sodium sulfate anhydrous are integral to numerous drug formulations, including laxatives, electrolyte solutions, and rehydration therapies. Their market dynamics are shaped by regulatory factors, manufacturing capacity, demand from pharmaceutical and consumer health sectors, and patent landscapes.

---

Market Overview

These active and excipient ingredients serve essential medical functions:

• Polyethylene glycol 3350 (PEG 3350): Used in over-the-counter bowel cleansing products and prescribed laxatives.
• Potassium chloride: Administered for electrolyte replenishment in hypokalemia and cardiac arrhythmia.
• Sodium bicarbonate: Used as an antacid and in alkalinizing agents.
• Sodium chloride: Applied in rehydration therapies and intravenous solutions.
• Sodium sulfate anhydrous: Functions as a laxative and osmotic agent.

Aggregate global sales of these ingredients are estimated at approximately $2.5 billion in 2022, driven primarily by North America, Europe, and Asia-Pacific. Demand forecasts indicate a compound annual growth rate (CAGR) of 4–6% through 2030, catalyzed by expanding healthcare access, aging populations, and increased adoption of electrolyte and bowel management therapies.

---

Market Drivers

• Aging Population and Chronic Disease: Older demographics require electrolyte repletion and bowel management, expanding demand for potassium chloride and PEG 3350.
• Generic Drug Expansion: Patent expirations for branded formulations increase reliance on bulk active ingredients.
• COVID-19 Impact: Elevated hygienic and rehydration needs temporarily boosted sodium chloride and sodium bicarbonate demand.
• Regulatory Approvals: Stringent quality standards from FDA, EMA, and other authorities influence manufacturing practices, with an increasing trend toward GMP certifications correlating to higher compliance costs but also enabling global distribution.

---

Market Constraints

• Supply Chain Disruptions: Raw material shortages, geopolitical tensions, and pandemic-related logistics issues have caused price volatility.
• Environmental Regulations: Stricter waste disposal and emissions standards, especially in Europe, increase manufacturing costs.
• Competitive Landscape: The market comprises major players like BASF, Sigma-Aldrich (Merck), and Huaqiang Rare Earths, with regional suppliers expanding their capacity to meet growing demand.

---

Financial Trajectory

Ingredient	2022 Revenue (USD millions)	2023-2030 CAGR	Key Trends
Polyethylene glycol 3350	700	5.0%	Growth driven by OTC laxatives, prescription drugs
Potassium chloride	600	4.5%	Demand in hypokalemia therapy, electrolyte replacement
Sodium bicarbonate	400	4.0%	Used in antacid formulations and in hospital settings
Sodium chloride	550	5.0%	Broad use in IV fluids, global rehydration protocols
Sodium sulfate anhydrous	250	4.5%	Niche market for laxatives, expanding via OEMs

Note: CAGR estimates are based on forecasts by industry analysts, considering ongoing market expansion, regulatory trends, and production scalability.

---

Regional Market Breakdown

• North America: Largest market share (~40%), driven by high healthcare expenditure and developed supply chains.
• Europe: Approximately 25%, with growth influenced by regulatory standards and aging populations.
• Asia-Pacific: Fastest growth (~7%), propelled by emerging markets, expanding healthcare infrastructure, and local manufacturing.

---

Regulatory and Patent Environment

Many formulations utilising these ingredients are off-patent or have limited patent protection, leading to increased commoditization. Regulatory compliance costs are rising, especially with the European Union's REACH regulations and stricter US Drug Quality and Security Act (DQSA) requirements.

Manufacturers are investing in GMP-certified production lines and sterile manufacturing facilities to meet evolving quality standards. These investments are pivotal in maintaining market share amid intensifying competition.

---

Investment and R&D Trends

• R&D is focusing on improving manufacturing efficiencies, reducing costs, and developing new formulations with enhanced bioavailability and stability.
• Companies explore biosynthetic alternative pathways to reduce reliance on petrochemical sources, aligning with sustainability mandates.
• Strategic acquisitions and partnerships are common, aimed at expanding production capacity and entering emerging markets.

---

Key Challenges and Opportunities

• Challenges: Raw material price swings, environmental compliance costs, and potential oversupply in commoditized ingredients.
• Opportunities: Growing demand in Asia-Pacific, new indications for existing ingredients, and advances in delivery mechanisms reducing dosage frequency.

---

Key Takeaways

• The global market for polyethylene glycol 3350, potassium chloride, sodium bicarbonate, sodium chloride, and sodium sulfate anhydrous exceeded $2.5 billion in 2022.
• CAGR projections of approximately 4–6% indicate sustained growth fueled by demographic trends, drug development, and supply chain expansion.
• Managed regulatory complexities and environmental considerations remain critical factors shaping manufacturing costs and market entry.
• Asia-Pacific presents rapid growth opportunities, with regional manufacturers increasingly capitalizing on local demand.
• Innovation centers on manufacturing costs, bioavailability, and sustainability, with R&D investments aimed at maintaining competitive advantage.

---

FAQs

1. What factors most influence prices for these ingredients?
Raw material costs, regulatory compliance expenses, supply chain stability, and demand fluctuations drive pricing.

2. Which regions are expanding fastest for these ingredients?
Asia-Pacific experiences the highest growth rates, followed by North America and Europe.

3. Are patents affecting market competitiveness?
Most formulations using these ingredients are off-patent, leading to commoditization and price competition.

4. What regulatory changes could impact future supply chains?
Environmental standards like REACH and FDA manufacturing guidelines can increase compliance costs and influence regional manufacturing decisions.

5. How might innovations impact market growth?
Improvements in manufacturing efficiency, sustainable sourcing, and delivery innovations can further drive demand and reduce costs.

---

Citations

[1] Industry analysis, PharmaMetrix, 2022.
[2] Market research reports, GlobalData, 2023.
[3] Regulatory updates, FDA and EMA, 2022.